Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles

被引:50
作者
Alhareth, Khairallah
Vauthier, Christine [1 ]
Bourasset, Fanchon [2 ]
Gueutin, Claire
Ponchel, Gilles
Moussa, Fathi [3 ]
机构
[1] Univ Paris Sud, CNRS, Fac Pharm, UMR 8612, F-92296 Chatenay Malabry, France
[2] Univ Paris Sud, Lab Pharm Clin, F-92296 Chatenay Malabry, France
[3] Univ Paris 11, LETIAM, IUT dOrsay, Orsay, France
关键词
Stealth nanoparticles; Nanoparticle surface; Dextran; Polysaccharide-coating; Anionic emulsion polymerization; PEGYLATED POLYCYANOACRYLATE NANOPARTICLES; POLY(ALKYLCYANOACRYLATE) NANOPARTICLES; DRUG-CARRIER; ACTIVATION; DELIVERY;
D O I
10.1016/j.ejpb.2012.03.009
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Recent reports showed that subtle modifications of nanoparticle surface properties induced dramatic changes of interactions with serum proteins. The present work was aimed to investigate the effect of the conformation of dextran chains decorating-the surface of poly(alkylcyanoacrylate) (PACA) nanoparticles on the pharmacokinetic and biodistribution of a model drug associated with the nanoparticles. Doxorubicin was associated with PACA nanoparticles prepared by anionic emulsion polymerization (AEP) (Dox-AEP) and redox radical emulsion polymerization (RREP) (Dox-RREP). Nanoparticles and the free drug (f-Dox) were injected intravenously to rats to determine the pharmacokinetic and biodistribution of doxorubicin. Curves of the pharmacokinetics showed a rapid phase of distribution followed by a slower elimination phase. Pharmacokinetic parameters of the distribution phase determined for the Dox-RREP were significantly different from those of f-Dox and Dox-AEP, while no difference was observed in the elimination phase of the three formulations. Rats treated with Dox-RREP showed lower Dox concentrations in liver but higher concentrations in heart, lungs, and kidneys compared to those treated with the other formulations. Dox-RREP exhibited a new type of stealth behavior characterized by a short circulation time and a rapid distribution in highly vascularized organs bypassing the MPS. The difference in pharmacokinetic and biodistribution observed between the drugs formulated with the two types of nanoparticles was attributed to the difference in the conformation of the dextran chains stranded on the nanoparticle surface. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:453 / 457
页数:5
相关论文
共 15 条
[1]
Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[2]
HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles [J].
Alhareth, Khairallah ;
Vauthier, Christine ;
Gueutin, Claire ;
Ponchel, Gilles ;
Moussa, Fathi .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 887 :128-132
[3]
Doxorubicin Loading and In Vitro Release from Poly(alkylcyanoacrylate) Nanoparticles Produced by Redox Radical Emulsion Polymerization [J].
Alhareth, Khairallah ;
Vauthier, Christine ;
Gueutin, Claire ;
Ponchel, Gilles ;
Moussa, Fathi .
JOURNAL OF APPLIED POLYMER SCIENCE, 2011, 119 (02) :816-822
[4]
Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: Influences of surface morphology, length, and type of polysaccharide [J].
Bertholon, Isabelle ;
Vauthier, Christine ;
Labarre, Denis .
PHARMACEUTICAL RESEARCH, 2006, 23 (06) :1313-1323
[5]
Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery [J].
Calvo, P ;
Gouritin, B ;
Chacun, H ;
Desmaële, D ;
D'Angelo, J ;
Noel, JP ;
Georgin, D ;
Fattal, E ;
Andreux, JP ;
Couvreur, P .
PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1157-1166
[6]
HEPATIC TISSUE DISTRIBUTION OF DOXORUBICIN-LOADED NANOPARTICLES AFTER IV ADMINISTRATION IN RETICULOSARCOMA M-5076 METASTASIS-BEARING MICE [J].
CHIANNILKULACHAI, N ;
AMMOURY, N ;
CAILLOU, B ;
DEVISSAGUET, JP ;
COUVREUR, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (02) :122-126
[7]
PHARMACOKINETICS AND DISTRIBUTION OF A BIODEGRADABLE DRUG-CARRIER [J].
GRISLAIN, L ;
COUVREUR, P ;
LENAERTS, V ;
ROLAND, M ;
DEPREZDECAMPENEERE, D ;
SPEISER, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1983, 15 (03) :335-345
[8]
Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush [J].
Labarre, D ;
Vauthier, C ;
Chauvierre, C ;
Petri, B ;
Müller, R ;
Chehimi, MM .
BIOMATERIALS, 2005, 26 (24) :5075-5084
[9]
Nanomedicine: current status and future prospects [J].
Moghimi, SM ;
Hunter, AC ;
Murray, JC .
FASEB JOURNAL, 2005, 19 (03) :311-330
[10]
Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting [J].
Peracchia, MT ;
Fattal, E ;
Desmaële, D ;
Besnard, M ;
Noël, JP ;
Gomis, JM ;
Appel, M ;
d'Angelo, J ;
Couvreur, P .
JOURNAL OF CONTROLLED RELEASE, 1999, 60 (01) :121-128